Healthcare / Medical DevicesTokyo
$975.00
-1.00 (-0.10%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $394.4M · quality 54.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$10.2B
P/E
40.0x
↑EV/EBITDA
4.6x
↓ROE
4.5%
↑Gross Margin
9.9%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.4%
FCF CAGR
-36.9%
FCF margin
0.8%
FCF / Net income
0.96x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $50.32B · net income $410.1M · FCF $394.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $50.32B | $50.32B | $45.85B | $47.48B | $45.50B |
| Net Income | $410.1M | $410.1M | $172.9M | $936.2M | $863.0M |
| EBITDA | $1.12B | $1.12B | $808.0M | $1.74B | $1.62B |
| EPS | 39.20 | 39.20 | 16.58 | 90.04 | 83.33 |
| Gross Margin | 9.9% | 9.9% | 10.4% | 11.5% | 11.7% |
| Operating Margin | 1.1% | 1.1% | 1.4% | 2.8% | 2.8% |
| Net Margin | 0.8% | 0.8% | 0.4% | 2.0% | 1.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Current Ratio | 1.42 | 1.42 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $394.4M | $394.4M | $-719.2M | $1.23B | $1.57B |
| Returns | |||||
| ROE | 4.5% | 4.5% | 1.9% | 10.1% | 10.0% |
| Valuation | |||||
| P/E | 39.96 | 39.96 | 59.95 | 10.75 | 12.23 |
| EV/EBITDA | 4.62 | 4.62 | 3.58 | 0.84 | 1.67 |
| P/B | 1.12 | 1.12 | 1.13 | 1.08 | 1.23 |
| Growth & Yield | |||||
| Revenue Growth | 9.8% | 9.8% | -3.4% | 4.4% | — |
| EPS Growth | 136.4% | 136.4% | -81.6% | 8.1% | — |
| Dividend Yield | 5.1% | 5.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
30.2%
EPS terminal req.
$86.52
Spread vs growth
106.2%
5Y implied EPS CAGR
21.7%
EPS terminal req.
$104.68
Spread vs growth
114.7%
10Y implied EPS CAGR
15.7%
EPS terminal req.
$168.59
Spread vs growth
120.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+14.3%
Start / end P/E
53.9x → 24.9x
EPS bridge
16.58 → 39.20
Residual
-73.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.